BRISTOL MYERS SQUIBB CO
Customers
4
4 active
Suppliers
3
2 active
Largest customer
36%
MCK · FY to 2025-12-31
Named-customer revenue
$41.9B
3 customers · FY to 2025-12-31
Latest period
Dec 31, 2025
10-K filed 2026-03-31
Customers 4
Companies BMY discloses as major customers, as a share of BMY revenue. 4 active, 0 lapsed.
| Company | % of BMY revenue | Est. revenue | Period | Trend | Status | Source |
|---|---|---|---|---|---|---|
| MCK Distributor MCKESSON CORP |
36% | $17.3B | FY 2025-12-31 | +2.0pp | Active | 10-K 2026-02-11 |
McKesson Corporation 36 % 34 % 33 % | ||||||
| COR Distributor Cencora, Inc. |
29% | $14.0B | FY 2025-12-31 | ±0.0pp | Active | 10-K 2026-02-11 |
Cencora, Inc. 29 % 29 % 29 % | ||||||
| CAH Distributor CARDINAL HEALTH INC |
22% | $10.6B | FY 2025-12-31 | ±0.0pp | Active | 10-K 2026-02-11 |
Cardinal Health, Inc. 22 % 22 % 23 % | ||||||
| ORIC Oric Pharmaceuticals, Inc. |
Named | — | FY 2025-12-31 | — | Active | 10-K 2026-02-23 |
In August 2020, the Company licensed from Mirati Therapeutics, Inc. development and commercialization rights to an allosteric inhibitor program directed towards the polycomb repressive complex 2 (PRC2) and in October 2020, the Company licensed from Voronoi Inc. development and commercialization rights to a brain-penetrant, orally bioavailable, irreversible inhibitor designed to selectively target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) with high potency against exon 20 mutations.As of December 31, 2025, the Company had an accumulated deficit of $692.2 million. | ||||||
Suppliers 3
Companies that disclose BMY as a major customer, as a share of their own revenue. 2 active, 1 lapsed.
| Company | % of their revenue | Est. $ from BMY | Period | Trend | Status | Source |
|---|---|---|---|---|---|---|
| BBIO BridgeBio Pharma, Inc. |
80.6% | $7.5M | FY 2023-12-31 | Lapsed Last seen 2023-12-31 |
10-K 2026-02-24 | |
Bristol-Myers Squibb Company (as described in Note 11) * * 80.6 % | ||||||
| CDXS CODEXIS, INC. |
Named | — | FY 2025-12-31 | — | Active | 10-K 2026-03-11 |
These companies include many of our large innovator and generic pharmaceutical customers, such as Merck, GSK, Novartis, Pfizer Inc., Bristol-Myers Squibb, Kyorin Pharmaceutical Corporation, and Teva Pharmaceuticals, which have significant internal research and development efforts directed at developing processes to manufacture APIs and intermediates. | ||||||
| PARA Parabolic Technologies, Inc. |
Named | — | FY 2025-12-31 | — | Active | 10-K 2026-03-31 |
OpenReel’s enterprise customer base includes global organizations, such as Bristol Myers Squibb, Ingram Micro, DXC Technology, Insider Inc., and US Steel. | ||||||
Alerts are coming
Get an email when BMY's disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.